Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18242091 | 0.82 | TP53 (0.52) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL25858165 | 0.81 | TP53 (0.50) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL9373403 | 0.81 | TP53 (0.50) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL7460990 | 0.79 | TP53 (0.48) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL7456749 | 0.79 | TP53 (0.48) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL4069342 | 0.79 | TP53 (0.48) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL2632875 | 0.79 | TP53 (0.59) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL16770543 | 0.79 | TP53 (0.59) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL17069212 | 0.79 | TP53 (0.59) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL16371578 | 0.78 | TP53 (0.47) | TP53LMNAHTTIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TP53 2492/4885LMNA 4863/4885HTT 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.